ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a ...
According to a news release from Northwest Normal University in Gansu province's capital of Lanzhou, researchers from the ...
Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...
Study Finds on MSN8d
Your clothes could soon charge your phone: New thermoelectric yarn makes it possibleScientists finally cracked the code on making fabric that can generate electricity from body heat by creating a special ...
Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late ...
AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...
Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's ...
About PEMGARDA PEMGARDA™ (pemivibart) is a half-life extended investigational ... on different populations and SARS-CoV-2 variants that are no longer circulating. Further, the variability associated ...
Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.
Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback